Article
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Cancer - 1 Aug 2015
Lo Peter C, Dahlberg Suzanne E, Nishino Mizuki, Johnson Bruce E, Sequist Lecia V, Jackman David M, Jänne Pasi A, Oxnard Geoffrey R
Abstract excerpt
BACKGROUND: Erlotinib is a highly active epidermal growth factor receptor (EGFR) kinase inhibitor that is approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests that this drug may provide continued disease control after patients develop objective progression of disease (PD), although this has not been systematically studied to date. METHODS: Patients who had Response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.